within Pharmacolibrary.Drugs.ATC.C;

model C05BB04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C05BB04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sodium tetradecyl sulfate is an anionic surfactant and sclerosing agent used primarily for the treatment of varicose veins and spider veins by intravenous injection. It induces sclerosis in veins by damaging the endothelium, resulting in occlusion of targeted vessels. The drug is approved for clinical use for sclerotherapy in many countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies in humans identified. Sodium tetradecyl sulfate is administered as a local sclerosant and is presumed to have minimal systemic absorption when used in intended local intravenous sclerotherapy for varicose veins in adults.</p><h4>References</h4><ol><li><p>Bai, T, et al., &amp; Fan, Y (2020). A Review of Sclerosing Foam Stability in the Treatment of Varicose Veins. <i>Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]</i> 46(2) 249–257. DOI:<a href=&quot;https://doi.org/10.1097/DSS.0000000000002039&quot;>10.1097/DSS.0000000000002039</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31569112/&quot;>https://pubmed.ncbi.nlm.nih.gov/31569112</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C05BB04;
